Literature DB >> 21945764

[Expressions of MACC1, HGF, and C-met protein in epithelial ovarian cancer and their significance].

Rui-tao Zhang1, Hui-rong Shi, Hao-liang Huang, Zhi-min Chen, Hui-na Liu, Zhong-fu Yuan.   

Abstract

OBJECTIVE: To investigate the expressions of metastasis-associated in colon cancer-1 (MACC1), hepatocyte growth factor (HGF), and C-met proteins in epithelial ovarian cancer and their significance.
METHODS: The expressions of MACC1, HGF and C-met in 20 specimens of normal ovarian tissues, 19 specimens of benign epithelial ovarian tumor and 52 specimens of epithelial ovarian cancer were measured by immunohistochemistry and Western blotting. The correlations of the expressions of MACC1, HGF and C-met protein to the clinicopathologic characteristics of epithelial ovarian cancer were analyzed, and the correlations between the expressions of the 3 proteins were also evaluated.
RESULTS: The positivity rates of MACC1, HGF and C-met proteins were 73.1%, 63.5% and 78.8% in epithelial ovarian cancer with relative expressions of 0.72∓0.05, 0.64∓0.04 and 0.79∓0.04, respectively, showing significant differences from those in normal ovarian tissues and benign ovarian tumors (P<0.05). In epithelial ovarian cancer, the up-regulation of MACC1, HGF and C-met expressions were associated with advanced FIGO stage, poor differentiation and lymph node metastasis (P<0.05). MACC1 expression was positively correlated to HGF (r=0.350, P=0.011) and C-met expressions (r=0.429, P=0.002), and the latter two was also positively correlated (r=0.487, P=0.000).
CONCLUSIONS: MACC1 may serve as a potential biomarker for advanced ovarian cancer. Deregulation of MACC1, HGF and C-met proteins may synergistically participate in the malignant progression of epithelial ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21945764

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  8 in total

1.  Genomic Profiling of Thyroid Cancer Reveals a Role for Thyroglobulin in Metastasis.

Authors:  Abdul K Siraj; Tariq Masoodi; Rong Bu; Shaham Beg; Saif S Al-Sobhi; Fouad Al-Dayel; Mohammed Al-Dawish; Fowzan S Alkuraya; Khawla S Al-Kuraya
Journal:  Am J Hum Genet       Date:  2016-05-26       Impact factor: 11.025

2.  MACC1 overexpression predicts a poor prognosis for non-small cell lung cancer.

Authors:  Zhiqiang Wang; Zhi Li; Chen Wu; Yonggong Wang; Yang Xia; Liang Chen; Quan Zhu; Yijiang Chen
Journal:  Med Oncol       Date:  2013-12-06       Impact factor: 3.064

3.  Circulating MACC1 as a novel diagnostic and prognostic biomarker for nonsmall cell lung cancer.

Authors:  Zhiqiang Wang; Ming Cai; Yuan Weng; Fang Zhang; Dong Meng; Jun Song; Huan Zhou; Zongtao Xie
Journal:  J Cancer Res Clin Oncol       Date:  2014-12-28       Impact factor: 4.553

4.  Prognostic value and clinical pathology of MACC-1 and c-MET expression in gastric carcinoma.

Authors:  Jie Ma; Jun Ma; Qun Meng; Zhong-Sheng Zhao; Wen-juan Xu
Journal:  Pathol Oncol Res       Date:  2013-07-01       Impact factor: 3.201

5.  Correlation of MACC1/c-Myc Expression in Endometrial Carcinoma with Clinical/Pathological Features or Prognosis.

Authors:  Qinghua Zhang; Ping Xu; Yanxia Lu; Hongtao Dou
Journal:  Med Sci Monit       Date:  2018-07-09

6.  Metastasis-associated in colon cancer 1: A promising biomarker for the metastasis and prognosis of colorectal cancer.

Authors:  He Li; Yi-Xin Chen; Jia-Gen Wen; Hong-Hao Zhou
Journal:  Oncol Lett       Date:  2017-07-26       Impact factor: 2.967

7.  MACC1 induces metastasis in ovarian carcinoma by upregulating hepatocyte growth factor receptor c-MET.

Authors:  Xiu-Jie Sheng; Zhen Li; Man Sun; Zhi-Hui Wang; Dong-Mei Zhou; Jian-Qi Li; Qin Zhao; Xiao-Fang Sun; Qi-Cai Liu
Journal:  Oncol Lett       Date:  2014-05-27       Impact factor: 2.967

8.  miR-148a-3p suppresses epithelial ovarian cancer progression primarily by targeting c-Met.

Authors:  Wen Wang; Jing Dong; Maoxiu Wang; Shujuan Yao; Xiangyu Tian; Xiujuan Cui; Shijie Fu; Shiqian Zhang
Journal:  Oncol Lett       Date:  2018-02-23       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.